SciSparc Ltd. (SPRC)
NASDAQ: SPRC · Real-Time Price · USD
6.79
-0.08 (-1.09%)
Aug 20, 2026, 1:26 PM EDT - Market open
SciSparc Revenue
In the year 2025, SciSparc had annual revenue of $856.00K, down -34.46%. SciSparc had revenue of $856.00K in the quarter ending December 31, 2025, a decrease of -34.46%.
Revenue (ttm)
$856.00K
Revenue Growth
-34.46%
P/S Ratio
4.59
Revenue / Employee
$285,333
Employees
3
Market Cap
3.89M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 856.00K | -450.00K | -34.46% |
| Dec 31, 2024 | 1.31M | -1.57M | -54.64% |
| Dec 31, 2023 | 2.88M | 1.53M | 113.73% |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Curis | 4.31M |
| GeoVax Labs | 852.28K |
| VivoSim Labs | 112.00K |
| Silo Pharma | 54.08K |
| Alaunos Therapeutics | 3.00K |
SPRC News
- 2 days ago - SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million - GlobeNewsWire
- 2 days ago - Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement - TheNewswire
- 7 days ago - NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement - TheNewswire
- 8 days ago - SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - GlobeNewsWire
- 8 days ago - NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination - TheNewswire
- 15 days ago - SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome - GlobeNewsWire
- 15 days ago - NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome - TheNewswire
- 20 days ago - SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics - GlobeNewsWire